Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. on August 6, 2019, reporting events that occurred on August 5, 2019. The Company is a Delaware corporation with its principal executive offices in Cambridge, MA, and its common stock trades on The Nasdaq Global Select Market under the symbol "MCRB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The Board of Directors increased the size of the Board from ten to eleven directors. Stephen Berenson was elected as a Class II director.
Management Commentary and Compensation Details
- Compensation: Mr. Berenson will participate in the standard compensation program for non-employee directors, including an annual retainer of $35,000.
- Equity Award: An initial award of an option to purchase 30,000 shares of common stock was granted.
- Option Terms: The exercise price is $2.44 per share (closing price on the grant date). The award vests in equal installments over four years, subject to continued service.
- Indemnification: Mr. Berenson has entered into the Company's standard indemnification agreement for directors and officers.
Investor Verification Checklist
- Verify the current total number of directors on the Board (now 11).
- Confirm the vesting schedule and exercise price of the 30,000 share option granted to Stephen Berenson.
- Review the Company's standard director compensation policy to confirm the $35,000 annual retainer aligns with other non-employee directors.
- Check subsequent filings for any changes to the Board composition or Mr. Berenson's tenure.